SCHEMBL25554309

SCHEMBL25554309

CC(=O)Nc1c[nH]c2ccc(COc3ccc(C)cc3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
MAOB P27338 5/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
PARP10 Q53GL7 1/20 0.43
LTA4H P09960 2/20 0.42
PLA2G2A P14555 2/20 0.42
ERAP1 Q9NZ08 1/20 0.42
STING1 Q86WV6 1/20 0.42
MAOA P21397 2/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25025875 0.89 MTNR1A (0.48) PPARGPPARDPPARARAB9AMEN1
SCHEMBL25025531 0.89 PPARG (0.46) PPARGPPARDPPARAMAOBNPC1
SCHEMBL25026130 0.87 MAOB (0.51) PPARGPPARDPPARAMAOBSTING1
SCHEMBL25554525 0.87 NPC1 (0.46) PPARGPPARDPPARAMAOBNPC1
SCHEMBL25554345 0.84 MTNR1A (0.56) PPARGPPARDPPARARAB9AMEN1
SCHEMBL25554406 0.84 LMNA (0.52) RAB9ASTING1MTNR1AMTNR1B
SCHEMBL25026032 0.83 CLK1 (0.43) RAB9AMEN1KMT2AMAPTALDH1A1
SCHEMBL6101206 0.82 LTA4H (0.56) MEN1POLBKMT2AMAPTALDH1A1
SCHEMBL25554403 0.82 MTNR1A (0.46) RAB9ASTING1MTNR1AMTNR1B
SCHEMBL25554260 0.82 PPARG (0.53) PPARGPPARDPPARAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 PPARG 1483/4885PPARD 2996/4885PPARA 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.